Results 231 to 240 of about 91,338 (326)

Artificial Intelligence for Bone: Theory, Methods, and Applications

open access: yesAdvanced Intelligent Discovery, EarlyView.
Advances in artificial intelligence (AI) offer the potential to improve bone research. The current review explores the contributions of AI to pathological study, biomarker discovery, drug design, and clinical diagnosis and prognosis of bone diseases. We envision that AI‐driven methodologies will enable identifying novel targets for drugs discovery. The
Dongfeng Yuan   +3 more
wiley   +1 more source

Toward Predictable Nanomedicine: Current Forecasting Frameworks for Nanoparticle–Biology Interactions

open access: yesAdvanced Intelligent Discovery, EarlyView.
Predictive models successfully screen nanoparticles for toxicity and cellular uptake. Yet, complex biological dynamics and sparse, nonstandardized data limit their accuracy. The field urgently needs integrated artificial intelligence/machine learning, systems biology, and open‐access data protocols to bridge the gap between materials science and safe ...
Mariya L. Ivanova   +4 more
wiley   +1 more source

Nerve Growth Factor in Diabetes Mellitus: Pathophysiological Mechanisms, Biomarkers and Therapeutic Opportunities. [PDF]

open access: yesPharmaceuticals (Basel)
Massimino M   +12 more
europepmc   +1 more source

La mort cel·lular en el desenvolupament del sistema nerviós [PDF]

open access: yes, 1996
Boix Torras, Jacint   +3 more
core  

Back Again to the Future: A New Era for Cerebroprotection

open access: yesAnnals of Neurology, EarlyView.
Cerebroprotection is a fresh framework for designing neurological therapy that targets glia and vascular cells, in addition to neurons. In the future, successful cerebroprotection will involve targeting all elements of the neurovascular unit. Preclinical trials must include functional outcomes, as well as lesion morphometry.
Patrick Lyden
wiley   +1 more source

Confined B‐Cell Reconstruction and High T‐Cell Clonality Define Clinical Response to Cladribine Treatment

open access: yesAnnals of Neurology, EarlyView.
Cladribine tablets are approved for relapsing multiple sclerosis, mediating their clinical effect by moderately depleting lymphocytes. In a prospective, monocentric study including 22 patients completing 2 annual cycles of cladribine, B‐ and T‐cell receptor repertoires and relapse activity were assessed at baseline and after 24 months. T‐cell clonality
Tilman Schneider‐Hohendorf   +8 more
wiley   +1 more source

Artery Tertiary Lymphoid Organs Form Neuroimmune Cardiovascular Interfaces in Atherosclerosis. [PDF]

open access: yesImmunol Rev
Mohanta SK   +10 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy